

AD \_\_\_\_\_

AWARD NUMBER DAMD17-97-1-7083

TITLE: Genetic Susceptibility Factors in Aggressive Breast Cancer  
in African-American Women and the Effects of Carcinogens and  
Modifiers

PRINCIPAL INVESTIGATOR: Keith W. Crawford, Ph.D.

CONTRACTING ORGANIZATION: Howard University College  
Washington, DC 20020

REPORT DATE: May 1998

TYPE OF REPORT: Annual

PREPARED FOR: Commander  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are  
those of the author(s) and should not be construed as an official  
Department of the Army position, policy or decision unless so  
designated by other documentation.

**DTIC QUALITY INSPECTED 1**

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
<small>Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.</small>				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE May 1998		3. REPORT TYPE AND DATES COVERED Annual (1 May 97 - 30 Apr 98)
4. TITLE AND SUBTITLE Genetic Susceptibility Factors in Aggressive Breast Cancer in African-American Women and the Effects of Carcinogens and Modifiers				5. FUNDING NUMBERS DAMD17-97-1-7083
6. AUTHOR(S) Crawford, Keith W., Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Howard University College Washington, DC 20020				8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSORING / MONITORING AGENCY REPORT NUMBER
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 words) The purpose of this study is to identify possible genetic risk factors that might predispose African-American women to aggressive breast cancer. Plasma samples collected from African-American women, both cases and controls would be used for genotyping, and tumor tissue samples were available from cases. The study proposed a genotypic analysis of carcinogen metabolizing genes and analysis of the p53 mutations in tumor samples to determine if associations exist between enzyme genotypes and cancer risk; and if an association exists between enzyme genotypes and p53 mutational patterns in tumors. Unfortunately, technical problems related to sample quality and difficulties in genotyping methodology have lead the mentor for this career development grant to terminate the project. Problems with the study design under which the samples were originally collected would further complicate analysis of any data that could be obtained. The principal investigator for the grant has identified a new laboratory and research project in which to continue the career development award. The plasma samples have been returned to the Howard University Cancer Center, our collaborators.				
14. SUBJECT TERMS Breast Cancer				15. NUMBER OF PAGES 13
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

\_\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

\_\_\_\_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

\_\_\_\_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

\_\_\_\_ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

\_\_\_\_ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

\_\_\_\_ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

\_\_\_\_ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Keith W. Crawford 5-26-88  
PI - Signature Date

**TABLE OF CONTENTS**

Introduction      Page 2

Body              Page 3

    Methods      page 3

    Results      page 4

References        Page 6

Appendices

## INTRODUCTION

The project is entitled *Genetic Susceptibility Factors in Aggressive Breast Cancer in African-American Women and the Effects of Carcinogens and Modifiers* (DAMD17-97-1-7083). The proposed study was designed to identify possible genetic risk factors predisposing African-American women to more aggressive forms of Breast Cancer. Enzymes involved in carcinogen activation and detoxification have polymorphic variants that may display differences in functional activity. The genetic profile for these enzymes may account for differences in the manner in which carcinogens are processed. The frequency of these polymorphisms vary across racial and ethnic populations and this may contribute to differences in disease prevalence between populations, when controlling for exposures.

Caucasians have a higher prevalence of breast cancer, but African-American women present with more aggressive disease, have a worse prognosis at diagnosis, and shorter survival. When socioeconomic factors are taken into account, these survival differences persist, suggesting the involvement of biologic processes (Eley et al., 1994). Mutations in the p53 tumor suppressor gene occur in over 50% of sporadic cancers (Cole et al., 1992). P53 mutational patterns may be predictive of prognosis in breast cancer. Some studies suggest that there are differences in mutational patterns between African-Americans and Caucasians (Blasyk et al., 1994, Shiao, et al., 1995). These differences could result from the genotypic profile that determines carcinogen metabolism and DNA damage to the target genes.

This study proposed a genotypic analysis of carcinogen metabolizing genes (Cytochrome P4501A1, CYP1A2, glutathione-S-transferases, acetyltransferases) and mutational analysis of the p53 mutations in tumor samples to determine whether:

- an association exists between enzyme genotypes and cancer risk when relevant exposures are present
- an association exists between enzyme genotype and p53 mutational patterns in tumors
- a model can be constructed to mechanistically account for the above associations, if detected

19980924 031

## BODY

## METHODS

### DNA Extraction from plasma samples

Using the method of Blomeke et al. (1997), 250  $\mu$ l of plasma was added to 750  $\mu$ l of buffer (50 mM TRIS-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA) and centrifuged at 300,00 g for 12 min (Sorvall RC M120). The pellets were resuspended in 200  $\mu$ l of lysis solution (0.1 % SDS; proteinase K, 1 mg/ml; RNase 20  $\mu$ g, Boehringer-Mannheim) and incubated at 65 C for 4-6 hours.. Each sample was extracted with an equal volume of buffer saturated phenol, and the resulting aqueous phase extracted with chloroform/iso-amyl alcohol (24:1). The resulting aqueous phase was adjusted to 3 M  $\text{NH}_4$ acetate and 10 mM MgCl. Glycogen (20  $\mu$ g, Boehringer-Mannheim) and cold 2-propanol (1 ml) were added to samples, which were centrifuged for 30 min at 14,000 rpm (Eppendorf 5415) at 4 C. Pellets were rinsed with 70% ETOH, air-dried and then resuspended in 20-40  $\mu$ l of distilled water.

### Quantification of DNA

DNA was quantified by fluorescence using a DyNA Quant 200 fluorometer (Hoefer Pharmacia Biotect). Total amounts recovered from samples ranged from 200 ng to 2000 ng, with recoveries averaging 35-45% of DNA present in the sample.

### Genotyping for N-Acetyl transferase 2

A Polymerase Chain Reaction (PCR)-assay was developed that amplified a 1093 bp fragment, encompassing the entire NAT2 coding sequence and part of the non-coding region (Bell et al., 1993). The assay mixture contained 10 pmoles of primers (TCTAGCATGAATCACTCTGC and GGAACAAATTGGACTTGG), 180 mM deoxynucleotide triphosphates, 10 mM Tris HCL, pH 8.3, 50 mM KCl, 30 mM  $\text{MgCl}_2$ , 20-100 ng of template DNA in a total volume of 100  $\mu$ l. PCR cycling conditions were : 96 C (4 min), 35 cycles of 96 C (1 min), 57 C (1.5 min), 72 C (3 min); and 72 C (7 min).

### NAT2 RFLP Genotyping

Four different Restriction fragment length polymorphisms (RFLP) have been reported, and restriction digests of the 1093 bp fragment produce the following patterns:

- M1 *Kpn*I Presence of the mutations produces two fragments 659, 443 bp
- M2 *a-Taq* presence of the mutation produces four fragments 381, 326, 226, 169 bp
- M3 *Bam* HI presence of the mutation produces two fragments 819, 283 bp

M4     *Msp*I     Presence of the mutation produce four fragments  
760, 188, 94, 60 bp

For nested PCR, the reaction uses 10 ul of reaction product from the reaction described above added to 90 ul of the same reaction mix containing different primers (5'-GAACTCTAGGAACAAATTGGACTTG-3', 5'-CCATCACCAGGTTTGGGAC-3') run under the same cycling conditions. An 817 bp fragment is produced.

## Results

Approximately 200 plasma samples were received from Howard University Cancer Center comprising breast cancer cases and age-matched controls. The samples were assigned LHC (Laboratory of Human Carcinogenesis) codes so the samples would remain blinded. Dr. Peter Shields, Chief of the Molecular Epidemiology section of NCI and the mentor for the training grant identified NAT2 as the first gene for us to genotype. The assay described in *Methods* was first done using our pedigree DNA sample set. This allowed experience to be acquired with the assay and a confirmation of the heritability of the polymorphisms.

When the DNA extraction procedure described above was applied to plasma samples available from the LHC lab, the recovery of DNA was comparable to that reported by Blomeke et al. based on quantification of DNA by measuring U.V. absorbance at 260 nm. However, the 260/280 ratio revealed that the seemingly high yields were due to protein contamination. The use of fluorescence to quantify the DNA is a procedure specific for DNA, and not affected by protein or RNA contamination. This allowed an accurate determination of DNA concentrations. The amount of DNA recovered varied based on the quantity of cells in the plasma samples and whether they were stored properly.

PCR amplification of DNA recovered was another source of problems. In some instances, inhibitors appeared to be present in the DNA from the extraction. Reducing the amount of DNA added to the assay apparently diluted out the inhibitors and resulted in PCR product, but this was not always the case. Preheating samples at 95 C for 15 minutes prior to addition in the PCR assay was attempted to inactivate inhibitors, but this produced limited success. Nested PCR was attempted to increase PCR yield and it worked in some samples but there was a concern as to whether results could be obtained for a sufficient number Howard University samples to conduct a meaningful statistical analysis.

In discussions between Dr. Shields and Dr. Lucile Adams-Campbell, Director of Howard University Cancer Center and collaborator with the research project, concerns were raised

about the original study design under which the samples were collected (*Breast cancer and Black Women: Gene and Environmental Interactions*, NIH-RO1CA55772) and whether the questions originally posed in this grant application could be answered accurately. These issues along with the technical problems related to the genotyping assays dampened Dr. Shields's enthusiasm for the project. The data from the genotyping was absolutely pivotal to answering the questions we posed, so Dr. Shields decided to terminate his sponsorship of the project (Appendix 1). The plasma samples have been returned to Howard University.

Ms. Juanita Bourne (appendix 2) and Dr. Patricia Muldrow at Ft. Detrick have been notified of these unfortunate circumstances, and they have instructed me to submit a new Statement of Work for a new project with a different mentor to continue with the training grant. Their request is being completed.

I am currently completing a book chapter in collaboration with Dr. Shields encompassing genetic polymorphisms and cancer risk. This activity has been a valuable component of the experience in the lab and has tremendously enhanced my career development training. The manuscript will be completed prior to July 1, 1998.



## REFERENCES

Bell, D., Taylor, J., Butler et al. , 1993, Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveal a new slow acetylator allele common in African-Americans. *Carcinogenesis* 14:1689-92

Blaszyk, H., Vaugn, C., Hartmann, A., et al. , 1994 Novel pattern of p53 gene mutations in American black cohort with high mortality from breast cancer. *Lancet* 343:1195-7

Blomeke, B., Bennett, W., Harris, C., Shields, P., 1997 Serum, plasma and paraffin-embedded tissues as a source of DNA for studying cancer susceptibility genes. *Carcinogenesis* 18:1271-5

Coles, C, Condie, A., Chetty, U, et al. 1992, p53 mutations in breast cancer. *Cancer Research* 52:5291-8

Eley, J., Hill, H., Chen, V. et al. (1994) Racial Differences in Survival from Breast Cancer. *JAMA* 272: 947-54

Shiao, Y., Chen, V., Scheer, W. et al., 1995, Racial Disparity in the Association of p53 Gene Alterations with Breast Cancer Survival. *Cancer Research* 55:1485-90



National Institutes of Health  
National Cancer Institute  
Bethesda, Maryland 20892

**MEMORANDUM**

**DATE:** May 7, 1998

**FROM:** Section Chief  
Molecular Epidemiology Section, LHC, DBS, NCI

**SUBJECT:** Status of activities and termination of breast cancer project

**To:** Kieth Crawford, Ph.D.

---

I would like to summarize for you our April 30, 1998 meeting. At the time I informed you of my decision to terminate our Howard University breast cancer project and collaboration as it relates to the DOD funding. This was a difficult decision for me, and I regret the inconvenience that it will cause you. The decision was based on both short-term and long-term considerations. Therefore, those activities should stop. Elise Bowman will assume the responsibility for the Howard University samples and ensure that they will be returned to Dr. Adams-Campbell or her designate.

For the interim period, we will continue your volunteer status in order to finish up the dopamine studies. You will receive appropriate credit through authorship for the genotyping of the dopamine D4 and DAT in the Mayo and UMD lung cancer studies, assuming that the analyses yield publishable data. However, the position of your authorship will be decided by me and Dr. Harris at the time that the data analysis is completed, and we can assess the relative contributions of all the authors. Your volunteer status will certainly continue until the laboratory components are completed.

Lastly, you and I are collaborating on a book chapter, and we should finish that work. You do not need volunteer status to complete this, however.

Please let me know if your new job status might impact on the completion of the above studies. And also let me know if there is anything that I can do to help you in your new job search.



Peter G. Shields, M.D.  
Building 37, Room 2C16  
37 Convent Drive MSC 4255  
Bethesda, MD 20892-4255  
Tele: 301-496-1603  
Fax: 301-402-8577  
E-Mail: Peter\_G\_Shields@NIH.GOV

cc: Dr. Harris  
Dr. Adams-Campbell  
Dr. Taylor

## HOWARD UNIVERSITY

COLLEGE OF MEDICINE  
DEPARTMENT OF PHARMACOLOGY

May 6, 1998

Ms. Juanita Bourne  
U.S. Army Medical and Materiel Command  
Breast Cancer Research Program  
Fort Detrick, Maryland

Dear Ms. Bourne,

On May 1, 1997, I was formally awarded a training grant, #DAMD17-97-1-7083 for a project entitled "Genetic Susceptibility Factors in Aggressive Breast Cancer in African-American Women". The study is a collaboration between Howard University Cancer Center and the Laboratory of Molecular Epidemiology in the National Cancer Institute. The research work is conducted at NCI under the mentorship of Dr. Peter Shields. The proposed study would determine if specific polymorphisms in enzymes involved in carcinogen activation and detoxification (CYP1a1, CYP2a1, CYP2e1, NAT enzymes, GST enzymes) are associated with the development of breast cancer. The study would further investigate whether certain polymorphisms were correlated with p53 mutational patterns. One hypothesis being tested is that variability in the frequencies of certain polymorphisms between Caucasian and African-American populations may contribute to differences in the biology of tumors. p53 mutations differ in their effect on protein function and cancer prognosis, and racial differences in p53 mutation patterns have been observed. The questions posed in the study would not only identify genetic risk factors but may reveal novel pathogenic mechanisms explaining population variability in p53 mutation patterns.

Approximately 200 plasma samples from breast cancer cases and controls were received from Howard University Cancer Center. DNA was extracted from the plasma samples. Unfortunately, the quality of the DNA did not permit PCR amplification. The quality of the DNA was essential to performing genotype analysis for the enzymes of interest. Numerous strategies for improving the yield from the extractions and the PCR were tried unsuccessfully. The number of samples that produced suitable PCR product were not sufficient to allow meaningful statistical analysis after genotyping. Because our hypotheses could not be tested in the absence of the genotype data, Dr. Shields determined that the study did not merit further pursuit. The samples are being returned to Howard University.

I am writing the Agency at this time requesting permission to continue the training grant in another laboratory within the National Cancer Institute. There would be no change in the cost or the award institution. At this point, I have identified at least two laboratories within NCI that have initially expressed an interest in allowing to train with them. Dr. Alfred Johnson in the Laboratory of Molecular Biology of NCI is studying the expression of epidermal growth factor receptors on cultured breast cells during the transformation process. Dr. Kevin Gardner in the Division of Clinical Science at NCI maps the functional domains of p53 tumor suppressor protein using deletion mutations to identify regions where p53 interacts with an array of other proteins involved in its cell-cycle regulatory functions and apoptotic functions.



Both of these researchers are exploring possible projects that would be suitable for a training grant, and I am also formulating ideas on my own. Upon the consent of the Agency, I would like to be allowed a period of time to develop and submit a revised research plan.

In spite of the difficulties encountered, I have benefitted tremendously in the period of less than a year that I have worked under the grant. While the samples from Howard University were being collected, coded and organized in their data base, I did work on a lung cancer case-control sample set from the University of Maryland. From working with that set I successfully extracted DNA from lymphocyte samples. I performed the genotyping for two genes related to dopamine pharmacology. Both of the genes, the dopamine transporter and the D4 Dopamine receptor subtype, express Variable number tandem repeat (VNTR) polymorphisms. This work was done from the University of Maryland samples (about 250 samples) and a sample set from the Mayo Clinic (about 100 samples). We are completing analysis of the data and publications are forthcoming.

I developed PCR assays to detect restriction fragment length polymorphisms and a VNTR polymorphism in the alpha4-subunit of the neuronal nicotinic receptor. I used single strand conformation polymorphism (SSCP) analysis to genotype the nicotinic VNTR polymorphism in a pedigree set in the lab. This same method would have been used to detect mutations in p53 genes breast tumor samples from Howard University.

Other activities that have contributed to my training include:


- completion of courses in Biostatistics and Epidemiology at the Johns Hopkins School of Public Health
- participation in departmental seminars of the Laboratory of Human Carcinogenesis
- participated in a symposium "Frontiers in Breast cancer" sponsored by Genequest Infosystems
- attended the American Association for Cancer Research annual meeting in New Orleans, 1998

In addition, I am co-authoring a chapter with Dr. Shields on *Cancer and Genetic Susceptibility* to be included in a book on Genetics and Disease.

Therefore, I have learned technical skills that are applicable in diverse research settings. I have also learned the most current paradigms of carcinogenesis and innovative approaches to both basic science and clinical research problems.

It is most unfortunate that the originally proposed work could not proceed as we had anticipated. I believe it would have made a contribution to our understanding of breast cancer risk factors and mechanisms of carcinogenesis. I am hopeful that the Agency will allow me to redirect my effort into a project that will be more fruitful. I can be reached at 301-402-2811. I appreciate your consideration of my request.

Sincerely,



Keith W. Crawford, Ph.D.

cc

Dr. Robert Taylor

Dept. of Pharmacology, Howard University College of Medicine